Protalix BioTherapeutics, Inc. Contracts & Agreements

Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (Filed With SEC on June 28, 2024)

Description of Capital Stock (Filed With SEC on March 14, 2024)

Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (Filed With SEC on August 7, 2023)

At the Market Offering Agreement, dated February 27, 2023, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on February 27, 2023)

Description of Capital Stock (Filed With SEC on February 27, 2023)

Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd (Filed With SEC on November 14, 2022)

Fill/Finish Agreement effective on August 29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd (Filed With SEC on November 14, 2022)

Letter Amendment dated May 2, 2022 (Filed With SEC on May 2, 2022)

Third Supplemental Indenture, dated as of August 24, 2021, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company,... (Filed With SEC on August 26, 2021)

Form of Exchange Agreement, dated as of August 12, 2021 among Protalix BioTherapeutics, Inc. and the Existing Holders (Filed With SEC on August 13, 2021)

At the Market Offering Agreement, dated July 2, 2021, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on July 2, 2021)

Technology Transfer and Supply Agreement made as of June 18, 2013 by and between Protalix Ltd. and Fundao Oswaldo Cruz (Filed With SEC on May 14, 2021)

Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A (Filed With SEC on May 14, 2021)

Amended and Restated Agreement between Protalix Ltd. and Comercio e Servios Ltda. dated June 17, 2013 (Filed With SEC on May 14, 2021)

Underwriting Agreement, dated February 11, 2021, between the Company and BofA Securities, Inc (Filed With SEC on February 16, 2021)

ATM Equity OfferingSM Sales Agreement, dated October 1, 2020, between the Company and BofA Securities, Inc (Filed With SEC on October 1, 2020)

Amended & Restated Protalix BioTherapeutics, Inc. 2006 Employee Stock Incentive Plan, as amended (Filed With SEC on August 10, 2020)

Form of Stock Option Agreement (Standard) (Filed With SEC on August 10, 2020)

Form of Stock Option Agreement (Executives) (Filed With SEC on August 10, 2020)

Amended and Restated Employment Agreement with Einat Brill Almon, Ph.D., dated June 7, 2020 (Filed With SEC on June 8, 2020)

Employment Agreement with Yael Hayon, Ph.D., dated June 7, 2020 (Filed With SEC on June 8, 2020)

Form of Securities Purchase Agreement (Filed With SEC on March 12, 2020)

Description of Capital Stock (Filed With SEC on March 12, 2020)

Form of Warrant (Filed With SEC on March 12, 2020)

Employment Agreement dated July 28, 2019 (Filed With SEC on July 29, 2019)

Employment Agreement dated May 20, 2019 (Filed With SEC on May 21, 2019)

Exclusive U.S. License and Supply Agreement dated as of July 23, 2018, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A (Filed With SEC on November 7, 2018)

Exclusive License and Supply Agreement dated as of October 17, 2017, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A (Filed With SEC on March 6, 2018)

Second Supplemental Indenture, dated as of November 27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust... (Filed With SEC on December 1, 2017)

EXCHANGE AGREEMENT by and among Protalix BioTherapeutics, Inc. and the Parties Signatory Hereto Dated as of July 24, 2017 (Filed With SEC on July 25, 2017)

NOTE PURCHASE AGREEMENT (Filed With SEC on July 25, 2017)

FORM OF FACE OF NOTE (Filed With SEC on July 25, 2017)

FIRST SupplementalIndenture between PROTALIXBIOTHERAPEUTICS, INC., as Issuer, ANDEACH OF THE GUARANTORS PARTY HERETO, and TheBank of New York Mellon Trust CoMPANY, N.A., as... (Filed With SEC on July 25, 2017)

Protalix BioTherapeutics, Inc. (Company) The Bank of New York Mellon Trust Company, N.A.,as Trustee (Trustee) 4.50% Convertible Senior Notes due 2022 INDENTURE Dated as of July... (Filed With SEC on July 25, 2017)

Principal Amount $22,500,000 as revised by the Schedule of Increases and Decreases of Global Note attached hereto Protalix BioTherapeutics, Inc. 7.50% Senior Secured Convertible... (Filed With SEC on December 7, 2016)

PROTALIX BIOTHERAPEUTICS, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 7.50% SENIOR SECURED CONVERTIBLE NOTESDUE 2021 INDENTURE DATED AS OF DECEMBER 7, 2016 THE BANK OF... (Filed With SEC on December 7, 2016)

Principal Amount $40,186,000 as revised by the Schedule of Increases and Decreases of Global Note attached hereto Protalix BioTherapeutics, Inc. 7.50% Senior Secured Convertible... (Filed With SEC on December 7, 2016)

FORM OF NOTE PURCHASE AGREEMENT (Filed With SEC on December 7, 2016)

FORM OF EXCHANGE AGREEMENT by and among Protalix BioTherapeutics, Inc. and the Parties Signatory Hereto Dated as of December 1, 2016 (Filed With SEC on December 7, 2016)

Dated 7 December 2016 BETWEEN PROTALIX BIOTHERAPEUTICS, INC. as the Company AND ALTSHULER SHAHAM TRUSTS LTD. as Security Trustee FORM OF SECURITY AGREEMENT/DEBENTURE UNLIMITED IN... (Filed With SEC on December 7, 2016)

FORM OF SECURITY AGREEMENT dated as of December 7, 2016 among PROTALIX BIOTHERAPEUTICS, INC. THE GUARANTORS PARTY HERETO and WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral... (Filed With SEC on December 7, 2016)

AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between PFIZER INC. and PROTALIX LTD. October 12, 2015 (Filed With SEC on November 9, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on September 29, 2014)

AGREEMENT (Filed With SEC on May 8, 2014)

TECHNOLOGYTRANSFER AND SUPPLY AGREEMENT (Filed With SEC on May 8, 2014)

Exhibit A (Filed With SEC on May 8, 2014)

ProtalixBioTherapeutics, Inc. (Company) The Bankof New York Mellon Trust Company, N.A. (Trustee) 4.50%Convertible Senior Notes due 2018 INDENTURE Datedas of September 18, 2013 (Filed With SEC on September 18, 2013)

[FACE OF NOTE] (Filed With SEC on September 18, 2013)

ProtalixBioTherapeutics, Inc. $60,000,0004.50% Convertible Notes Due 2018 PurchaseAgreement (Filed With SEC on September 18, 2013)

FORM OF RESTRICTED STOCK AGREEMENT/NOTICE PROTALIX BIOTHERAPEUTICS, INC. 2006 STOCK INCENTIVE PLAN, AS AMENDED NOTICE OF RESTRICTED STOCK AWARD (Filed With SEC on July 18, 2012)

Protalix BioTherapeutics, Inc. 4,500,000 Shares Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on February 16, 2012)

Protalix BioTherapeutics, Inc. (Filed With SEC on March 18, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on December 22, 2009)

UNPROTECTED LEASE Executed and signed in Tel-Aviv on January 13, 2008 (Filed With SEC on March 17, 2008)

RESEARCH AND LICENSE AGREEMENT (Filed With SEC on November 14, 2007)

Underwriting Agreement (Filed With SEC on October 25, 2007)

RESEARCH AND LICENCE AGREEMENT (Filed With SEC on September 20, 2007)

AGREEMENT made and signed on this 14 day of September, 2006 (Filed With SEC on September 20, 2007)

LICENSE AGREEMENT (Filed With SEC on September 20, 2007)

SCIENTIFICADVISORY BOARD AGREEMENT (Filed With SEC on August 6, 2007)

EX-4.1 Form of Warrant (Filed With SEC on January 8, 2007)

EX-10.1 2006 Stock Incentive Plan (Filed With SEC on January 8, 2007)

EX-10.2 Employment Agreement w/Yoseph Shaaltiel (Filed With SEC on January 8, 2007)

EX-10.3 Employment Agreement w/Einat Almon (Filed With SEC on January 8, 2007)

EX-10.4 Employment Agreement w/David Aviezer (Filed With SEC on January 8, 2007)

EX-10.5 Employment Agreement w/Yossi Maimon (Filed With SEC on January 8, 2007)

EX-10.6 License Agreement (Filed With SEC on January 8, 2007)

EX-10.7 Research and License Agreement (Filed With SEC on January 8, 2007)

EX-10.8 Agreement between Teva and Protalix (Filed With SEC on January 8, 2007)

EX-10-9 Unprotected Lease Contract (Filed With SEC on January 8, 2007)

EX-10.10 Merger Agreement and Plan (Filed With SEC on January 8, 2007)

Category

Industry

Companies

Contracts

Protalix BioTherapeutics, Inc. Contracts & Agreements